Betahistine Hydrochloride

Phase 1Small molecule

EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Betahistine Hydrochloride is one of 36 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Attention Deficit Hyperactivity DisorderActive, not recruiting

Attention Deficit Hyperactivity DisorderPhase 1

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Attention Deficit Hyperactivity Disorder

#DrugCompanyPhaseTrials

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

2 2

Provigil

NNuvo Research GmbH

Phase 3

1 3

Catapres

Boehringer Ingelheim

Phase 3

1 4

OROS Oxybutynin

Johnson & Johnson

Phase 3

4 5

Ambien

PPurdue Pharma LP

Phase 3

1 6

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 7

Ritalin

Pfizer

Phase 3

5 8

Cymbalta

Alnylam Pharmaceuticals

Phase 2

1 9

Adderall-XR

NNew River Pharmaceuticals

Phase 3

2 10

Concerta

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder1 trial

Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder

Completed·PP2D, Inc.·Phase 1·NCT00829881·16 enrolled

Overweight1 trial

Effects of Betahistine Hydrochloride in Overweight Women

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 1·NCT00459992·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Betahistine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Betahistine Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Betahistine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Betahistine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder1 trial

Overweight1 trial

References

Drug Info

Quick Facts

Related News